Area of research
Reproductive Medicine · Oncology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Cancer Genomics and Diagnostics, and CRISPR and Genetic Engineering.
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Feasibility of Microlearning for Improving the Self-Efficacy of Cancer Patients Managing Side Effects of Chemotherapy
Concurrent RB1 loss and <i>BRCA</i> -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma
Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
A Systematic Review of Electronic Medical Record Driven Quality Measurement and Feedback Systems
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci
Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp> CD8 <sup>+</sup> TIL </scp> infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas
MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma
Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin
Multidisciplinary teams and ICT: a qualitative study exploring the use of technology and its impact on multidisciplinary team meetings
Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
MyD88 and TLR4 Expression in Epithelial Ovarian Cancer
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Dose-Response Association of CD8<sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study
<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer
Whole–genome characterization of chemoresistant ovarian cancer
ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer
Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis